574013-66-4

574013-66-4 structure

Name: Fexaramine
Chemical Name: Fexaramine,3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester
CAS Number: 574013-66-4
Molecular Formula: C₃₂H₃₆N₂O₃
Molecular Weight: 496.64000
Catalog: Signaling Pathways Metabolic Enzyme/Protease FXR
Create Date: 2017-01-21 17:31:30
Modify Date: 2026-07-03 14:31:46
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds. IC50 value:Target:in vitro: In vitro treatment of CDCA or fexaramine elevated the SHP transcript level and occupancy on secretin promoter [1]. Fexaramine significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and β-catenin signaling [2]. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver [3].

Name	Fexaramine,3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester
Synonyms	Fexamine, 10 mM in DMSO 2-Propenoic acid, 3-[3-[(cyclohexylcbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-, methyl ester, (2E) (2E,4Z)-5-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecboxamido)phenyl)-4-(methoxycbonyl)penta-2,4-dienoic acid Fexamine Methyl (E)-3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecboxamido)phenyl)acrylate Actosp Dasan 3-[3-[(Cyclohexylcbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-pr (E)-methyl 3-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecboxamido)phenyl)acrylate 2-Propenoic acid, 3-[3-[(cyclohexylcbonyl)[[4'-(diMethylaMino)[1,1'-biphenyl]-4-yl]Methyl]amino]phenyl]-, Methyl ester 3-[3-[(Cyclohexylcbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-Propenoic acid methyl ester 3-[3-[(Cyclohexylcbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester (E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecboxamido)phenyl)acrylate

Description	Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds. IC50 value:Target:in vitro: In vitro treatment of CDCA or fexaramine elevated the SHP transcript level and occupancy on secretin promoter [1]. Fexaramine significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and β-catenin signaling [2]. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver [3].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> FXR Research Areas >> Others
References	[1]. Lam IP, et al. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G90-7. [2]. Cho SW, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013 Oct;28(10):2109-21. [3]. Fang S, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb;21(2):159-65.

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302-H413
Precautionary Statements	P301 + P312 + P330
RIDADR	NONH for all modes of transport